Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)

"1. Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling

2. Has at least one HbA1C (Hemoglobin a1c) measurement obtained within the three (3) months prior to the start date of first Dexcom CGM System use in the study (blinded or unblinded, whichever first). For participants with prior CGM experience (CGM non-naive), this HbA1c measurement must also be at least three (3) months after the end of any CGM usewithin three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use

3. Participant is willing and able to use Dexcom CGM System according to approved product labeling

4. Participant is willing and able to complete applicable patient reported outcome assessments/ surveys